<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976882</url>
  </required_header>
  <id_info>
    <org_study_id>HR-TPO-CIT-Ⅲ</org_study_id>
    <nct_id>NCT03976882</nct_id>
  </id_info>
  <brief_title>Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Multicentre Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and&#xD;
      safety of Hetrombopag in subjects with chemotherapy-induced thrombocytopenia receiving&#xD;
      chemotherapy for the treatment of solid tumors and lymphomas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of responders.</measure>
    <time_frame>Up to the end of Cycle 2 (each cycle is 21 or 28 days)</time_frame>
    <description>Responder is defined as proportion of subjects who do not require platelet transfusion or platelet boosting therapy (rhTPO or rhIL11) in Cycle 1, dose reduction in chemotherapy by &gt;20%, or chemotherapy delay by &gt;4 days in Cycle 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration from initiating chemotherapy to the time presenting the nadir of platelet count</measure>
    <time_frame>Up to the end of Cycle 1 (each cycle is 21 or 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who do not require platelet transfusion or platelet boosting therapy (rhTPO or rhIL11)</measure>
    <time_frame>Up to the end of Cycle 1 (each cycle is 21 or 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who do not require dose reduction in chemotherapy by &gt;20%</measure>
    <time_frame>Up to the end of Cycle 2 (each cycle is 21 or 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who do not require chemotherapy delay by &gt;4 days</measure>
    <time_frame>Up to the end of Cycle 2 (each cycle is 21 or 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Chemotherapy-Induced Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Hetrombopag treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study is 2:1 randomization ratio (hetrombopag to placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study is 2:1 randomization ratio (hetrombopag to placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag</intervention_name>
    <description>Hetrombopag oral tablet 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.</description>
    <arm_group_label>Hetrombopag treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral tablet (vehicle) 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, 18-75 years of age;&#xD;
&#xD;
          -  Participant with a confirmed diagnosis of solid tumor or lymphoma by histopathological&#xD;
             or cytological examination receiving a chemotherapy regimen given in a 21 or 28-day&#xD;
             cycle, including 1 or more of the following agents or class of agents: Antimetabolie&#xD;
             Antineoplastic agents including gemcitabine, Antitumor Platinum drugs including&#xD;
             Carboplatin or cisplatin, Anthracycline Alkylating agent, Alkylating agent or other&#xD;
             chemotherapy which could induce thrombocytopenia;&#xD;
&#xD;
          -  Participant experienced moderate thrombocytopenia, defined as two platelet counts&#xD;
             within 30×109-75×109/L measured at least 24 h apart, during the previous chemotherapy&#xD;
             cycle;&#xD;
&#xD;
          -  In the previous day before dosing of Hemtrombopag (Day -1), subjects has a platelet&#xD;
             count within 100×109-200×109/L, neutrophil count≥1.5×109/L, haemoglobin≥90g/L;&#xD;
&#xD;
          -  Subject has a life expectancy≥12 weeks at screening and is able to receive at least&#xD;
             two additional cycles of the current chemotherapy regimen when screening;&#xD;
&#xD;
          -  ECOG performance status 0-1;&#xD;
&#xD;
          -  Subjects of childbearing potential must agree to use a highly effective method of&#xD;
             contraception, except subjects with surgically sterile;&#xD;
&#xD;
          -  Subject is willing to participate in the study, and Subject must provide written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has experienced thrombocytopenia due to any etiology other than chemotherapy&#xD;
             within 6 months of Screening;&#xD;
&#xD;
          -  Subject has any history of hematologic diseases other than lymphoma and CIT;&#xD;
&#xD;
          -  Solid tumor with invasion of bone marrow;&#xD;
&#xD;
          -  Subject has received radiotherapy;&#xD;
&#xD;
          -  Subject has a history of arterial or venous thrombosis within 6 months of Screening;&#xD;
&#xD;
          -  Subject has a history of significant cardiovascular disease (eg, congestive heart&#xD;
             failure New York Heart Association Grade 3/4, arrhythmia known to increase the risk of&#xD;
             thromboembolic events (eg, atrial fibrillation), coronary artery stent placement,&#xD;
             angioplasty, or coronary artery bypass graft;&#xD;
&#xD;
          -  Subject has previously received a thrombopoietin receptor agonist (eg, eltrombopag),&#xD;
             rhTPO or rhIL11 for the treatment of CIT;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ling Li, MD</last_name>
    <phone>86-400-828-3900</phone>
    <email>liling@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Najing Bayi Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shukui Qin, MD</last_name>
      <phone>86-025-80864362</phone>
      <email>qinsk@csco.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

